Phosphodiesterase Inhibitors: A Therapeutic Approach for Arsenic- Induced Neurotoxicity
Sonia Bhatt1, Ajay Pal Singh1, Sokindra Kumar2
1School of Pharmacy, Lingaya's Vidyapeeth, Nachauli, Faridabad, India.
Drug Metabolism and Bioanalysis Letters
|April 29, 2025
Summary
Arsenic exposure damages the brain, but PDE4 and PDE1 inhibitors rolipram and vinpocetine show promise. These drugs improved brain health and reduced neurotoxicity in rats exposed to arsenic.
Area of Science:
- Neuroscience
- Toxicology
- Pharmacology
Background:
- Arsenic toxicity is a significant global health concern.
- Chronic arsenic exposure leads to cognitive impairment in developing and adult brains.
- Sodium arsenite induces neurotoxicity, affecting brain development and function.
Purpose of the Study:
- To investigate the neuroprotective effects of rolipram (a PDE4 inhibitor) and vinpocetine (a PDE1 inhibitor) against sodium arsenite-induced neurotoxicity in Sprague-Dawley rats.
- To evaluate the impact of these inhibitors on biochemical markers and protein expression in the hippocampus.
Main Methods:
- Arsenic concentration in blood was measured to assess accumulation.
- Brain weight was evaluated as an indicator of neurotoxicity.
- Biochemical assays were performed for malondialdehyde (MDA), glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD).
- Protein expression of CREB (cAMP response element-binding protein) and P-CREB was analyzed in hippocampal tissue.
Main Results:
- Rolipram and vinpocetine significantly improved brain weight, counteracting arsenic-induced reduction.
- Administration of these inhibitors reversed decreased antioxidant activity and reduced inflammation.
- Both rolipram and vinpocetine notably increased CREB and P-CREB expression in the rat hippocampus.
Conclusions:
- Inhibition of phosphodiesterase 4 (PDE4) and phosphodiesterase 1 (PDE1) offers a potential therapeutic strategy for arsenic-induced neurotoxicity.
- Rolipram and vinpocetine demonstrate neuroprotective properties against arsenic toxicity.
- Targeting PDE4 and PDE1 may represent a novel drug therapy for mitigating arsenic-induced brain damage.
Related Concept Videos
01:26Anticholinesterase Agents: Poisoning and Treatment
733
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
733
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
551
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
551
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
473
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
473
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
85
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
85